Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;10 Suppl 2(Suppl 2):S62-S74.
doi: 10.1002/sctm.20-0495.

Umbilical cord blood transplantation: Still growing and improving

Xiaoyu Zhu  1   2   3 , Baolin Tang  1   2   3 , Zimin Sun  1   2   3
Affiliations
Review

Umbilical cord blood transplantation: Still growing and improving

Xiaoyu Zhu et al. Stem Cells Transl Med. 2021 Nov.

Abstract

Umbilical cord blood transplantation (UCBT) has been performed in the clinic for over 30 years. The biological and immunological characteristics of umbilical cord blood (UCB) have been re-recognized in recent years. UCB, previously considered medical waste, is rich in hematopoietic stem cells (HSCs), which are naïve and more energetic and more easily expanded than other stem cells. UCB has been identified as a reliable source of HSCs for allogeneic hematopoietic stem cell transplantation (allo-HSCT). UCBT has several advantages over other methods, including no harm to mothers and donors, an off-the-shelf product for urgent use, less stringent HLA match, lower incidence and severity of chronic graft-vs-host disease (GVHD), and probably a stronger graft-vs-leukemia effect, especially for minimal residual disease-positive patients before transplant. Recent studies have shown that the outcome of UCBT has been improved and is comparable to other types of allo-HSCT. Currently, UCBT is widely used in malignant, nonmalignant, hematological, congenital and metabolic diseases. The number of UCB banks and transplantation procedures increased exponentially before 2013. However, the number of UCBTs increased steadily in Asia and China but decreased in the United States and Europe year-on-year from 2013 to 2019. In this review, we focus on the development of UCBT over the past 30 years, the challenges it faces and the strategies for future improvement, including increasing UCB numbers, cord blood unit selection, conditioning regimens and GVHD prophylaxis for UCBT, and management of complications of UCBT.

Keywords: graft-vs-host disease; graft-vs-leukemia; stem cell; transplantation; umbilical cord blood.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Shipments of HPC cords provided by the continents from WMDA and the number of UCBTs in China from CBMTR from 2010‐2019
See this image and copyright information in PMC

References

    1. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51:786‐792. - PMC - PubMed
    1. Lv M, Huang XJ. Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. J Hematol Oncol. 2012;5:10. - PMC - PubMed
    1. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem‐cell grafts in the U.S. registry. N Engl J Med. 2014;371:339‐348. - PMC - PubMed
    1. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical‐cord blood from an HLA‐identical sibling. N Engl J Med. 1989;321:1174‐1178. - PubMed
    1. Milano F, Gooley T, Wood B, et al. Cord‐blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944‐953. - PMC - PubMed

Publication types

MeSH terms